Altimmune (NASDAQ:ALT) executives highlighted recent clinical and regulatory milestones for pemvidutide and outlined plans to advance a Phase 3 program in metabolic dysfunction-associated steatohepatitis (MASH) during a presentation at the Leerink Partners Global Healthcare Conference. 2025 readouts and FDA feedback set stage for Phase 3 Chief Executive Officer Jerry Durso said 2025 featured two readouts […]